Lasa Supergenerics Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Get Lasa Supergenerics Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
quick-summary-circle
company-logo

Click to see a quick summary and important updates about this stock!Dismiss

Lasa Supergenerics Ltd.

BSE: 540702, NSE: LASA

  • Market Capitalisation market-capitalisation-info ₹106 Cr
  • 12 Month Earnings monthly-earning ₹-11 Cr
  • Price to Earnings price-to-earning --

₹21.15

As on 23-Mar-2023 IST

up-down-arrow ₹-0.50 • -2.31%

  • Prev Close info

    ₹21.65

  • Day's Openinfo

    ₹21.90

  • Today's Highinfo

    ₹21.90

  • Today's Lowinfo

    ₹21.05

  • Today's Volumeinfo

    62,716

Stock Performance
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Lasa Supergenerics
-37.15 -16.90 -36.87 -51.93 -14.89 -24.91 --
S&P BSE Healthcare
-5.99 -1.51 -8.03 -10.38 21.77 10.24 10.54
S&P BSE Small Cap
-6.18 -1.70 -4.51 -2.56 38.96 9.72 16.74
As on 23-Mar-2023
2022
2021
2020
2019
2018
Lasa Supergenerics
-50.95 -18.77 354.84 -43.44 -84.13
S&P BSE Small Cap
-1.80 62.77 32.11 -6.85 -23.41
S&P BSE Healthcare
-12.10 20.87 61.45 -3.55 -5.89

Valuation
Stock
Peer Median

Growth & Efficiency
Stock
Peer Median

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

View Details arrow

Peer Comparison

search
search
search
search
    Comparison Details arrow

    Valuation Chart of Lasa Supergenerics Ltd.

        Financials

        View Details arrow

        Shareholding Pattern

        View Details arrow

        News & Analysis of Lasa Supergenerics Ltd.

        No Review & Analysis are available.

        All News arrow

        Incorporated

        2016

        Chairman

        Omkar Pravin Herlekar

        Managing Director

        Omkar Pravin Herlekar

        Headquarters

        Mahad, Maharashtra

        Website

        www.lasalabs.com
        More Details arrow
        Edit peer-selector-edit

        Key Facts

        • Market cap market-cap-information ₹106.42 Cr
        • Revenue (TTM)revenue-information ₹145.46 Cr
        • Earnings (TTM) earning-information ₹-11.33 Cr
        • Cash date-information ₹3.24 Cr
        • Total Debt info ₹20.17 Cr
        • Promoters' ownership promoters_ownership 43.78%
        • Liquidity liquidity Moderate
        • 52 Week range week-range ₹21.00 - 65.50
        • Face value face-value ₹10.00
        • Shares outstanding share-outstanding 5,01,01,239
        • 7 Years Aggregate:

          CFO: ₹143.08 Cr

          EBITDA: ₹190.66 Cr

          Net Profit: ₹23.71 Cr

        About The Company

        • Business Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol.
        • Incorporated 2016
        • Chairman Omkar Pravin Herlekar
        • Managing Director Omkar Pravin Herlekar
        • Listing key-listing BSE: 540702, NSE: LASA
        • Country India
        • Headquarters headquarters Mahad, Maharashtra
        • Website website www.lasalabs.com
        Add Portfolio by-stock Add to watchlist watchlist-stock-modal Share Download Stock Report
        Portfolio stock-portfolio Watchlist watchlist-stock-modal share-fund-icon Download Stock Report
        Portfolio stock-investment Watchlist add-watchlist-icon share-fund-plan-icon